脑欣康胶囊治疗气虚血瘀痰阻型缺血性中风恢复期56例疗效观察(1)
【摘要】 目的：观察脑欣康胶囊治疗气虚血瘀痰阻型缺血性中风恢复期的临床疗效。方法：选取2011年1月-2012年12月笔者所在医院收治的107例病情趋于稳定的中风患者作为研究对象，采用随机双盲、双模拟、平行对照研究方法将其分为试验组56例和对照组51例。试验组给予脑欣康胶囊治疗，对照组给予血塞通片治疗，观察比较两组患者的中医症候疗效及治疗前后血液动力学变化情况。结果：经治疗后，试验组的治疗总有效率87.50%(49/56)明显高于对照组的70.59%(36/51)，差异有统计学意义(字2=4.674，P=0.031)；两组血液动力学指标均明显低于治疗前，且试验组治疗后的血液动力学指标均明显低于对照组，差异均有统计学意义(P<0.05)。结论：采用脑欣康胶囊治疗气虚血瘀痰阻型缺血性中风恢复期的治疗效果显著，具有安全性和有效性，使用方便，值得临床推广。
【关键词】 脑欣康胶囊； 缺血性中风； 恢复期； 临床观察
中图分类号 R255.2 文献标识码 B 文章编号 1674-6805(2014)35-0097-03
, 百拇医药
【Abstract】 Objective：To observe the clinical effect of Naoxinkang Capsule in the treatment of qi deficiency，blood and phlegm stagnation syndrome of ischemic stroke recovery period.Method：107 stroke patients with condition tends to be stable in our hospital from January 2011 to December 2012 were selected，using randomized，double-blind，double-dummy，parallel control study method，they were divided into the experimental group for 56 cases and the control group for 51 cases.The experimental group was given Naoxinkang Capsule for treatment，the control group was given Xuesaitong Tablets for treatment.The clinical efficacy and the changes of hemodynamics before and after treatment between the two groups were observed and compared.Result：After treatment，the total effective rate of experimental group was 87.50%(49/56)，it was significantly higher than 70.59%(36/51) of control group，the difference was statistically significant(字2=4.674，P=0.031).The hemodynamic indexes of the two groups after treatment were significantly lower than before treatment，and the hemodynamic indexes of experimental group after treatment were significantly lower than control group，the differences were statistically significant(P<0.05).Conclusion：Naoxinkang Capsule in the treatment of qi deficiency，blood and phlegm stagnation syndrome of ischemic stroke recovery period has the remarkable curative effect，safety and effectiveness，easy to use，is worthy of clinical promotion.
, 百拇医药
【Key words】 Naoxinkang Capsule； Ischemic apoplexy； Recovery； Clinical observation
脑中风是神经系统常见病和多发病，具有高发病率、致残率的特点，其中缺血性脑中风的发病率为出血性的3倍。缺血性中风又称脑卒中，是由于阴阳失衡，气血逆乱上犯于脑所引起的以突然昏仆、不省人事、口舌歪斜、半身不遂、不经昏仆，仅以半身不遂，言语不利，口舌歪斜，偏身麻木为主要表现的一种病证[1]。其中50%～70%的存活者遗留瘫痪、失语等严重残疾，给社会和家庭带来沉重负担，因此，对脑中风恢复期的治疗显得尤为重要。本文通过对56例缺血性中风恢复期患者给予口服脑欣康胶囊进行治疗，观察其临床疗效，现具体报告如下。
1 资料与方法
1.1 一般资料
选取2011年1月-2012年12月笔者所在医院收治的107例中风患者作为研究对象，所有患者病情趋于稳定，神志清楚，能正常合作，脑梗死均经颅脑CT检查，均符合诊断标准。采用随机双盲、双模拟、平行对照研究方法将所有患者分为试验组56例和对照组51例。试验组56例患者中，男35例，女21例，年龄42～78岁，平均(60.10±8.46)岁；病程67～197 d，平均(128.14±36.01)d；对照组51例患者中，男32例，女19例，年龄38～76岁，平均(59.41±9.36)岁；病程75～174 d，平均(116.29±29.32)d。两组患者的性别、年龄、梗死部位及病程等一般资料比较差异均无统计学意义(P>0.05)，具有可比性。, 百拇医药(孙玉勇)
【关键词】 脑欣康胶囊； 缺血性中风； 恢复期； 临床观察
中图分类号 R255.2 文献标识码 B 文章编号 1674-6805(2014)35-0097-03
, 百拇医药
【Abstract】 Objective：To observe the clinical effect of Naoxinkang Capsule in the treatment of qi deficiency，blood and phlegm stagnation syndrome of ischemic stroke recovery period.Method：107 stroke patients with condition tends to be stable in our hospital from January 2011 to December 2012 were selected，using randomized，double-blind，double-dummy，parallel control study method，they were divided into the experimental group for 56 cases and the control group for 51 cases.The experimental group was given Naoxinkang Capsule for treatment，the control group was given Xuesaitong Tablets for treatment.The clinical efficacy and the changes of hemodynamics before and after treatment between the two groups were observed and compared.Result：After treatment，the total effective rate of experimental group was 87.50%(49/56)，it was significantly higher than 70.59%(36/51) of control group，the difference was statistically significant(字2=4.674，P=0.031).The hemodynamic indexes of the two groups after treatment were significantly lower than before treatment，and the hemodynamic indexes of experimental group after treatment were significantly lower than control group，the differences were statistically significant(P<0.05).Conclusion：Naoxinkang Capsule in the treatment of qi deficiency，blood and phlegm stagnation syndrome of ischemic stroke recovery period has the remarkable curative effect，safety and effectiveness，easy to use，is worthy of clinical promotion.
, 百拇医药
【Key words】 Naoxinkang Capsule； Ischemic apoplexy； Recovery； Clinical observation
脑中风是神经系统常见病和多发病，具有高发病率、致残率的特点，其中缺血性脑中风的发病率为出血性的3倍。缺血性中风又称脑卒中，是由于阴阳失衡，气血逆乱上犯于脑所引起的以突然昏仆、不省人事、口舌歪斜、半身不遂、不经昏仆，仅以半身不遂，言语不利，口舌歪斜，偏身麻木为主要表现的一种病证[1]。其中50%～70%的存活者遗留瘫痪、失语等严重残疾，给社会和家庭带来沉重负担，因此，对脑中风恢复期的治疗显得尤为重要。本文通过对56例缺血性中风恢复期患者给予口服脑欣康胶囊进行治疗，观察其临床疗效，现具体报告如下。
1 资料与方法
1.1 一般资料
选取2011年1月-2012年12月笔者所在医院收治的107例中风患者作为研究对象，所有患者病情趋于稳定，神志清楚，能正常合作，脑梗死均经颅脑CT检查，均符合诊断标准。采用随机双盲、双模拟、平行对照研究方法将所有患者分为试验组56例和对照组51例。试验组56例患者中，男35例，女21例，年龄42～78岁，平均(60.10±8.46)岁；病程67～197 d，平均(128.14±36.01)d；对照组51例患者中，男32例，女19例，年龄38～76岁，平均(59.41±9.36)岁；病程75～174 d，平均(116.29±29.32)d。两组患者的性别、年龄、梗死部位及病程等一般资料比较差异均无统计学意义(P>0.05)，具有可比性。, 百拇医药(孙玉勇)
参见：首页 > 医疗版 > 疾病专题 > 神经内科 > 脑血管病 > 中风(脑卒中)